Loading clinical trials...
Loading clinical trials...
A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Double Lung Transplant
Conditions
Interventions
Liposomal Cyclosporine A
Standard of Care
Locations
40
United States
Banner Health
Phoenix, Arizona, United States
UCLA Medical Center
Los Angeles, California, United States
Stanford University Hospital
Palo Alto, California, United States
UC San Francisco
San Francisco, California, United States
University of Florida Medical Center
Gainesville, Florida, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Start Date
March 26, 2019
Primary Completion Date
March 12, 2024
Completion Date
March 12, 2024
Last Updated
February 10, 2026
NCT07046910
NCT02812290
NCT06399302
NCT06018766
NCT05375149
NCT07316829
Lead Sponsor
Zambon SpA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions